|Videos|June 15, 2021

Dr. Chung-Han Lee discusses ongoing pembrolizumab/lenvatinib trial in non-clear cell RCC

Chung-Han Lee, MD, PhD, discusses the ongoing open-label phase 2 KEYNOTE-B61 study of frontline pembrolizumab plus lenvatinib in non-clear cell renal cell carcinoma.

First study author Chung-Han Lee, MD, PhD, discusses the ongoing open-label phase 2 KEYNOTE-B61 study of frontline pembrolizumab (Keytruda) plus lenvatinib (Lenvima) in non-clear cell renal cell carcinoma. Lee, a medical oncologist at Memorial Sloan Kettering Cancer Center, shared a poster highlighting this study as part of the trials in progress session at the 2021 ASCO Annual Meeting.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Subscribe Now!

Related Content

Latest CME

Breakthroughs in Non–Muscle-Invasive Bladder Cancer: Advancing Patient Care Through Innovation in Treatment
Virtual Event

Breakthroughs in Non–Muscle-Invasive Bladder Cancer: Advancing Patient Care Through Innovation in Treatment

February 23, 2026

View more
Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD
Video

Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD

Glenn M. Chertow, MD, MPH; Anil K. Agarwal, MD, FACP, FASN, FNKF, FASDIN; Preethi Yerram, MD

View more